Lifecore Wins Multi-Year Deal with Lindy Biosciences, Expected to Generate $5M in Revenue
Portfolio Pulse from Benzinga Newsdesk
Lifecore Biomedical, Inc. (NASDAQ:LFCR) has secured a multi-year contract with Lindy Biosciences to provide CDMO services for Lindy's microglassification technology, potentially generating over $5 million in revenue. This positions Lifecore as Lindy's preferred CDMO partner.
October 01, 2024 | 11:01 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lifecore Biomedical has been selected by Lindy Biosciences for a multi-year CDMO services contract, expected to generate over $5 million in revenue. This deal enhances Lifecore's position in the biotech sector.
The multi-year agreement with Lindy Biosciences is a significant win for Lifecore, potentially adding over $5 million in revenue. This positions Lifecore as a key player in the biotech CDMO space, likely boosting investor confidence and stock price in the short term.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90